Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3220](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3220) → GWD — Indirect Fluorescent Antibody Test, Entamoeba Histolytica & Rel Sp

# GWD · Indirect Fluorescent Antibody Test, Entamoeba Histolytica & Rel Sp

_Microbiology · 21 CFR 866.3220 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GWD

## Overview

- **Product Code:** GWD
- **Device Name:** Indirect Fluorescent Antibody Test, Entamoeba Histolytica & Rel Sp
- **Regulation:** [21 CFR 866.3220](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3220)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

Entamoeba histolytica serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Entamoeba histolytica in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify Entamoeba histolytica directly from clinical specimens. The identification aids in the diagnosis of amebiasis caused by the microscopic protozoan parasite Entamoeba histolytica and provides epidemiological information on diseases caused by this parasite. The parasite may invade the skin, liver, intestines, lungs, and diaphragm, causing disease conditions such as indolent ulcers, an amebic hepatitis, amebic dysentery, and pulmonary lesions.

## Classification Rationale

Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.

## Special Controls

*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K873299](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GWD/K873299.md) | MERIFLUOR(TM)-GIARDIA | Meridian Diagnostics, Inc. | Sep 16, 1987 | SESE |
| [K844836](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GWD/K844836.md) | HEMOCLIP X-20 AUTOMATIC HEMOCLIP LIGATING APPLIER | Edward Weck, Inc. | Jan 23, 1985 | SESE |

## Top Applicants

- Edward Weck, Inc. — 1 clearance
- Meridian Diagnostics, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GWD](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GWD)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com